Aarti Industries Limited — Q2 FY26 earnings call

Call held 14 Nov 2025

Management summary

Aarti Industries delivered strong sequential growth in Q2 FY26, with significant increases in revenue, EBITDA, and PAT, primarily driven by improved volumes and operating leverage. Despite near-term challenges like US tariffs and competitive pricing, the company is focused on market diversification, cost optimization, and strategic capacity expansions. Several new facilities are slated for commissioning in the coming quarters, supporting future growth and product flexibility.

Highlights

  • Revenue stood at ₹2,250 crores, an increase of 21% Quarter-on-Quarter (Q-o-Q) driven by improved volumes.

  • EBITDA surged to ₹292 crores, marking a 36% Q-o-Q increase, fueled by improved capacity utilization and cost optimization.

  • Profit After Tax (PAT) was ₹106 crores, an increase of about 150% Q-o-Q, reflecting improved operating leverage.

  • CAPEX for the quarter was ₹267 crores, with a full-year FY26 guidance of around ₹1,000 crores.

  • The company is commissioning a Calcium Chloride facility this quarter and a new Multipurpose Plant (MPP) in Q4 FY26.

  • MMA delivered strong performance with highest-ever quarterly volumes, despite US tariffs, through market diversification.

  • Cost optimization initiatives worth ₹150-200 crores are underway, with 40-50% of benefits yet to flow to the bottom line.

Concerns

  • US tariffs on Indian chemical exports

Key financials

2 periods

Headline

  • Revenue
    ₹2,250 Cr
    QoQ +21%
  • EBITDA
    ₹292 Cr
    QoQ +36%
  • PAT
    ₹106 Cr
    QoQ +150%

Q2 FY26

  • Capex
    ₹267 Cr

What they filed

Q1 FY27: revenue up 37.0%, net profit up 227.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,717 1,749 1,992 1,636 2,084 +21%2,276 +30%2,439 +22%2,241 +37%
EBITDA199 230 265 212 284 +43%318 +38%349 +32%366 +73%
Net profit55 47 99 44 102 +85%131 +179%147 +48%144 +227%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex ₹267 Cr this quarter · ₹1,000 Cr (FY26) planned
    • Zone 4 expansion, including a new Multipurpose Plant (MPP)
    • Calcium Chloride facility
    • PEDA (2-Phenyl Ethyl Diethyl Aniline) project (4,000 TPA)
    • MMA debottlenecking efforts
    • 5 incremental blocks in Zone 4
    CAPEX for the quarter was at Rs. 267 crore and is expected to be around Rs. 1,000 crore for the year FY26, as guided earlier, reflecting continued capital discipline. Our Zone 4 expansion project continues to progress as planned, with newer capacities expected to come online over the next few quarters. A new multipurpose plant (MPP) within Zone 4 is expected to be commissioned in Q4 FY26, enhancing flexibility in product development. In parallel, the Calcium Chloride facility is expected to be commissioned in this ongoing quarter. As one of the growth projects in forward integration, we are set to commission a new 4,000 TPA PEDA (2-Phenyl Ethyl Diethyl Aniline) project in Zone 4, in Jhagadia. It will utilize raw materials from our Ethylation capacity in Dahej and it will position us as one of the key domestic suppliers to support India's agrochemical industry and capitalize on the demand trend that we are currently seeing. In addition to that, in the next quarter, which is Q4 of FY '26, we are also planning to commission a slightly increased capacity of MMA based on the debottlenecking effort and in addition to that, one specific molecule PEDA, again, which will become a form of MPP. Post that, there are 5 blocks, incremental blocks in Zone 4. I think each of the blocks will get sort of sequentially commissioned throughout the next financial year.
  • Debt Debt disclosed
    We actually think from a debt-to-EBITDA point of view, we potentially could have already seen the peak. Absolute debt numbers are important. But for us, I think what we track more is debt-to-EBITDA. And I think on that front, we feel that we could have potentially already seen the peak now, and it should improve going forward.

Guidance & targets

Capex

  • FY26 Capex Capex · FY26 · High confidence around ₹1,000 crores
    CAPEX for the quarter was at Rs. 267 crore and is expected to be around Rs. 1,000 crore for the year FY26, as guided earlier, reflecting continued capital discipline

    — Suyog Kotecha

  • FY27 Capex Capex · FY27 · Medium confidence substantially lower than ₹1,000 crores
    So capex for next year will be substantially lower than INR1,000 crore. We do not have the right number. We are still yet to work out the numbers, but it will be substantially lower.

    — Chetan Gandhi

Tax Rate

  • Effective Tax Rate Tax Rate · FY27 · Medium confidence below 15%
    On the tax rate, I anticipate FY '27, we should be somewhere at a number below 15%.

    — Chetan Gandhi

  • Effective Tax Rate Tax Rate · FY28 · Medium confidence between 15% to 20%
    And FY '28, we should be between 15% to 20%. That is a rough estimate right now.

    — Chetan Gandhi

Capacity Commissioning

  • Calcium Chloride facility Capacity Commissioning · Q2 FY26 (ongoing quarter) · High confidence commissioned
    In parallel, the Calcium Chloride facility is expected to be commissioned in this ongoing quarter.

    — Suyog Kotecha

  • Multipurpose Plant (MPP) within Zone 4 Capacity Commissioning · Q4 FY26 · High confidence commissioned
    A new multipurpose plant (MPP) within Zone 4 is expected to be commissioned in Q4 FY26, enhancing flexibility in product development.

    — Suyog Kotecha

  • PEDA (2-Phenyl Ethyl Diethyl Aniline) project Capacity Commissioning · Q3 FY26 (next quarter) · High confidence commissioned
    In addition to that, in the next quarter, which is Q4 of FY '26, we are also planning to commission a slightly increased capacity of MMA based on the debottlenecking effort and in addition to that, one specific molecule PEDA, again, which will become a form of MPP.

    — Suyog Kotecha

  • Incremental blocks in Zone 4 Capacity Commissioning · throughout next financial year (FY27) · High confidence sequentially commissioned
    Post that, there are 5 blocks, incremental blocks in Zone 4. I think each of the blocks will get sort of sequentially commissioned throughout the next financial year.

    — Suyog Kotecha

Cost Optimization

  • Benefit flow-through Cost Optimization · next financial year (FY27) · Medium confidence 40-50% of ₹150-200 crores yet to flow
    I think we have given a number of INR150 crore to INR200 crore for which the action is completed, I would say roughly 40% to 50% of it is yet to flow through in the bottom line.

    — Suyog Kotecha

Product Mix

  • Energy segment contribution Product Mix · steady-state (after Zone 4 capacity) · Medium confidence 30-40%
    On a steady-state basis, again, we mentioned it previously, we feel given the entire Zone 4 new capacity, new products will also come on stream over the course of next 1.5 years. The energy as a segment ultimately might settle down somewhere in the range of 30% to 40%.

    — Suyog Kotecha

CDMO

  • Large-scale business CDMO · 18-24 months · Low confidence 18-24 month journey
    That work converting into a concrete large-scale business in terms of manufacturing or supplying of a particular intermediate/chemical. That is kind of an 18 to 24-month journey in sort of our sense.

    — Suyog Kotecha

What to watch in Q3 FY26

Calcium Chloride facility commissioning

next quarter
Current Expected this quarter (Q2 FY26)
Target Commercial operations confirmed

Why it matters

Indicates progress on new capacity additions and potential revenue streams.

In parallel, the Calcium Chloride facility is expected to be commissioned in this ongoing quarter.

Risks & concerns

  • US tariffs on Indian chemical exports

    high

    Represents a near-term headwind, temporarily eroding competitiveness against European and Chinese suppliers.

    Management acknowledged

  • Complex geopolitical backdrop

    medium

    The external operating environment continues to evolve amid a complex geopolitical backdrop.

    Management acknowledged

  • Competitive pricing from China and domestic players

    medium

    Ongoing competitive pricing challenges for MMA and aggressive competitive pricing for high-value fluoro products.

    Management acknowledged

  • Volatile demand environment

    medium

    The macro level continues to navigate a volatile but gradually improving demand environment.

    Management acknowledged

  • Raw material and product pricing volatility

    medium

    Volatility in the market, both in terms of raw material and product pricing, remains elevated.

    Management acknowledged

Q&A highlights

8 direct
Sustainability of margin improvement and impact of product mix Direct
The margin's improvement was predominantly driven by operating leverage. At a contribution level, if you see at the overall product portfolio level, we remain quite consistent on the contribution margin level. But as the overall business volume goes up, the operating leverage starts kicking in and that starts getting reflected in the EBITDA percentage increase.

Clarifies that margin improvement is due to operating leverage from higher volumes, not necessarily a shift to higher-margin products, indicating sustainability if volumes are maintained.

Asked by Arun Prasath

Commissioning timeline and impact of new plants (Zone 4, PEDA, MMA) Direct
So what we can say at this point in time is, in this quarter, we will commission a calcium chloride facility. In the next quarter, we are commissioning our multipurpose plant, both of these are at Zone 4. In addition to that, in the next quarter, which is Q4 of FY '26, we are also planning to commission a slightly increased capacity of MMA based on the debottlenecking effort and in addition to that, one specific molecule PEDA, again, which will become a form of MPP. Post that, there are 5 blocks, incremental blocks in Zone 4. I think each of the blocks will get sort of sequentially commissioned throughout the next financial year.

Provides a clear roadmap for capacity additions and their timelines, crucial for future volume and revenue growth.

Asked by Arun Prasath

Future end-category mix and capital allocation strategy Direct
If you look at, at least from a strategic planning perspective, we feel energy will remain in kind of 30% to 40% range and the share of Agro, polymer specifically, these two end-applications, along with a little bit of pharma will inch up as we execute on our strategic plans. That is what is on the cards. How it evolves in reality, I think all of us will observe and see, but that is where we see kind of a resolved state at the end of 2-2.5 years. ... I do not think at this point in time, we are thinking about sort of the next level of large investment, which is sort of INR1,000 crore plus kind of a ticket size, which is what we did at Zone 4. I think for the next few years, the focus will remain on sort of relatively medium ticket size projects, which can be turned around quickly based on existing infrastructure, at the same time, significantly accrue to the bottom line.

Outlines the company's long-term product mix strategy and a shift towards medium-ticket, quick-turnaround capex projects for better financial returns, rather than large-scale investments.

Asked by Arun Prasath

Mitigation strategies for US tariff impacts Direct
I think the only couple of levers that have worked for us, and we continue to push that is sort of having the proactive conversations with customers to ensure that the relationship remains intact and the business remains intact where both sides have to compromise to some extent and the second aspect is, I think the product portfolio, which is potentially re-exported out of U.S. There, there are strategic levers which can be applied to minimize the overall tariff impact there.

Details the company's approach to managing the adverse effects of US tariffs, focusing on customer engagement and product portfolio adjustments.

Asked by Arun Prasath

Rationale for PEDA expansion and value chain integration Direct
I think we enter into a product where we feel we can have global competitiveness and we can have a global scale play. This is one value chain where we are developing end-to-end integration. So we will start from all the way basic petrochemical building blocks, and we will go all the way downstream. And we also feel that we will be able to do this with a distinctive competitive cost advantage.

Explains the strategic importance of the PEDA project as a move towards end-to-end value chain integration and building global competitiveness.

Asked by Archit Joshi

Progress on CDMO opportunities Direct
Yes, we have started our work in that dimension. I think we have good initial success. But currently, where we are in that sort of we are getting to know and build relationships with some of the global innovators. As we speak, we are doing sort of 3 or 4 projects, which are at R&D level. So I think the focus remains on building relationships with global innovators and trying to get involved in the very early part of a development cycle. That work converting into a concrete large-scale business in terms of manufacturing or supplying of a particular intermediate/chemical. That is kind of an 18 to 24-month journey in sort of our sense.

Provides an update on the nascent but promising CDMO business, highlighting R&D-level projects and the long-term nature of scaling up.

Asked by Archit Joshi

Increase in debtor levels Direct
So if you look at the top line, the top line has also gone up. And in certain cases, in fact, just adding it to the previous question which was there, the export percentage is upwards of 60%, where the credit profile is a bit more as compared to the domestic numbers, so which is where you would see this receivable to be there. So if I combine on an overall working capital basis, the working capital cycle continues to remain at the level what it was. It continues to remain in the range of around 45, 50-odd days.

Explains the increase in debtor days as a consequence of a higher export percentage (over 60%), which typically involves longer credit periods compared to domestic sales.

Asked by Anil Chaurasia

Discrepancy between finance cost in P&L and cash flow Direct
So as I said that there is the mark-to-market impact on the loans, which has to be accounted based on the volatility of the currency and is not a cash flow item and that is where the cash flow will show the actual cash outgo versus the P&L will reflect the provisioning for those potential volatility impacts as well.

Clarifies that the difference is due to non-cash mark-to-market adjustments on loans, which impacts the P&L but not the cash flow statement.

Asked by Anil Chaurasia

2 min read 6 chapters

Detailed narrative

Strong Sequential Performance Despite Market Headwinds

Aarti Industries reported robust sequential growth in Q2 FY26, with revenue increasing by 21% Q-o-Q to ₹2,250 crores. This was primarily driven by improved volumes across key product categories. EBITDA saw an even stronger surge of 36% Q-o-Q to ₹292 crores, benefiting from enhanced capacity utilization and ongoing cost optimization initiatives. Consequently, Profit After Tax (PAT) jumped by approximately 150% Q-o-Q to ₹106 crores, reflecting improved operating leverage.

Strategic Response to US Tariffs and Market Diversification

The company acknowledged US tariffs on Indian chemical exports as a near-term headwind, impacting competitiveness. In response, Aarti Industries has actively diversified its export mix towards Europe, the Middle East, and Africa, while recalibrating its US strategy. Management noted that while Q2 FY26 saw pain from US tariffs, this was offset by growth in other geographies. They anticipate policy clarity and normalization of trade flows in the medium term, with a potential India-US trade deal acting as a significant catalyst.

Capacity Expansion and Project Commissioning Pipeline

Aarti Industries is progressing with its Zone 4 expansion project. A Calcium Chloride facility is expected to be commissioned in the current quarter (Q2 FY26), followed by a new Multipurpose Plant (MPP) in Q4 FY26. Additionally, a 4,000 TPA PEDA project in Jhagadia, utilizing raw materials from existing Ethylation capacity, is set for commissioning in Q3 FY26. Further MMA debottlenecking and 5 incremental chemistry-oriented blocks in Zone 4 are planned for sequential commissioning throughout FY27, enhancing product flexibility and integration.

Cost Optimization and Margin Outlook

The company has implemented cost optimization initiatives targeting ₹150-200 crores in benefits. Management indicated that roughly 40-50% of these benefits are yet to flow through to the bottom line, with a significant portion expected in FY27, particularly from renewable power purchase agreements. While raw material and product pricing volatility remains high, sustained volumes are expected to drive operating leverage and support margin expansion.

Product Segment Performance and Future Mix

MMA delivered its highest-ever quarterly volumes, driven by spill-over demand from Q1 and diversification efforts. The energy segment's contribution is expected to stabilize at 30-40% in the steady state after Zone 4 capacity comes online, with agro, polymer, and pharma segments gradually increasing their share. The DCB segment, though negative year-on-year, showed quarter-on-quarter recovery from a weak Q1, with a revised strategy aiming for a strong second half.

Capital Expenditure and Debt Strategy

Capex for Q2 FY26 was ₹267 crores, with the full-year FY26 guidance maintained at around ₹1,000 crores. For FY27, capex is projected to be substantially lower than ₹1,000 crores. The company's capital allocation strategy is shifting towards medium-ticket projects that offer quick turnaround and significant returns, leveraging existing infrastructure. Management believes the debt-to-EBITDA ratio may have already peaked, indicating a focus on improving leverage going forward.

This is an AI-generated summary of a publicly available earnings call transcript.